TIFFANY SPARKS: Open Payments
NPI 1770077885 · ALBERTVILLE, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,638 in 164 payments from 25 companies in 2025. Trend: 2023 $2,538 · 2024 $2,471 · 2025 $2,638
Food & beverage: $2,638
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 30 | $424 |
| Novo Nordisk Inc | 15 | $259 |
| Bayer Healthcare Pharmaceuticals Inc. | 13 | $237 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 12 | $223 |
| AstraZeneca Pharmaceuticals LP | 13 | $218 |
| PFIZER INC. | 16 | $217 |
| Sumitomo Pharma America, Inc. | 19 | $186 |
| Phathom Pharmaceuticals, Inc. | 6 | $143 |
| Amgen Inc. | 7 | $115 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 6 | $99 |
Products named: Kerendia, VRAYLAR, CAPLYTA, GEMTESA, VOQUEZNA, FARXIGA, QULIPTA, Ozempic.
Industry payments across AL — which companies pay providers there.
